Comparative Pharmacology
Head-to-head clinical analysis: CECLOR versus CEFADYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR versus CEFADYL.
CECLOR vs CEFADYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It exhibits bactericidal activity against susceptible organisms.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation.
250 mg orally every 8 hours; for severe infections, 500 mg orally every 8 hours.
1-2 g IV/IM every 6 hours for moderate to severe infections; maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life: 0.6-0.9 hours in adults with normal renal function. Prolonged to 2-3 hours in end-stage renal disease. Half-life does not increase significantly with hepatic impairment.
30-60 minutes in adults with normal renal function; prolonged to 10-20 hours in end-stage renal disease. Requires dose adjustment for CrCl <30 mL/min.
Primarily renal: 80-90% of unchanged drug excreted by glomerular filtration and tubular secretion within 8 hours. Biliary excretion accounts for <5%; fecal elimination negligible.
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary: <1%. Fecal: minimal.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic